Baxter Launches Artiss [solutions For Sealant]

Jan. 10, 2012 - PRLog -- COMPTON, UK 28th November: Baxter UK today announced the launch of Artiss, the only premixed, ready-to-use slow-setting fibrin sealant specifically designed to seal and adhere subcutaneous tissue in plastic, reconstructive and burn surgery as well as helping to improve haemostasis on subcutaneous tissue surfaces1.

                       During plastic, reconstructive and burns procedures, the use of staples or sutures often leaves a dead space underneath tissue flaps or skin grafts, which can lead to post-operative fluid accumulation such as haematoma or seroma as complications3,5.  A spray application of Artiss over the wound bed gives surgeons 60 seconds in which to manipulate and accurately position the tissue2,4 to ensure a tight seal and achieve full surface adherence  to the subcutaneous tissue. The elimination of dead space reduces drainage volumes, the occurrence of haematoma and seroma and thus reduces post-operative complications 3,5,6, .

           Clinical studies have shown that Artiss is well-tolerated and effective as a alternative to staples for attaching skin grafts in burn patients, with outcomes at least as good as staples, but with significantly less haematoma/seroma on Artiss-treated sites on day one.5,6

           Plastic Surgeon Professor Paul McArthur, from Whiston Hospital and Alder Hey Children’s Hospital, Merseyside said. “This is great news. Eliminating the need to remove staples means that patients, particularly young children, will not undergo what is a painful procedure or require an additional anaesthetic event.  If Artiss proves to be as effective for other plastic and reconstructive surgery procedures, minimising areas of dead space, and significantly reducing drainage volumes when compared to standard of care, then early drain removal or drain free surgery, could mean patients going home sooner, freeing up beds and similarly reducing NHS costs.”

           Baxter Hospital Products Business Unit Director Andy Goldney said, “I am delighted that we have launched this innovative product for use within surgery.  This further enhances the range of products that we offer to the NHS within our BioSurgery business to enhance and speed up recovery of patients who have undergone surgery.”

           Artiss is also approved in the UK for use in plastic and reconstructive surgery for the adhesion of tissue flaps, for example in face-lift surgery (facial rhytidectomy).

           The phase 3 clinical study also reported that patients had less pain and anxiety related to their Artiss-treated sites, where the sealant replaced staples for skin graft fixation. Pain and anxiety are usually associated with staple removal.6

           
About Artiss
Artiss [Solutions for Sealant], Vapour Heated, Solvent Detergent Treated, is a two-component fibrin sealant made from pooled human plasma. When combined, the two components, Sealer Protein (Human) and Thrombin (Human), mimic the final stage of the blood coagulation cascade.
In Europe, Artiss is indicated as a tissue glue to adhere/seal subcutaneous tissue in plastic, reconstructive and burn surgery, as a replacement or an adjunct to sutures or staples, as well as an adjunct to haemostasis on subcutaneous tissue surfaces.

# # #

Baxter Healthcare Ltd. is the primary domestic operating subsidiary of Baxter International Inc. . Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.